entertainment -WSS

entertainment

author：entertainment 2025-09-06 04:41:25 - browse：857

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Why you get paid to donate plasma but not blood

focus

WSS

SCOTUS to consider access to abortion pill mifepristone

CMS should re

Radiology is caught between AI's potential and concern for patients

More hospitals are billing patients as online messages surge

Teach medical students about patients with intellectual disabilities

A Theranos scientist

hotspot

entertainment

hotspot

Cancer drug shortages should be causing more outrage

Flagship, Pfizer team up in deal worth up to $7 billion

Malaria cases in Florida and Texas: Here’s what you need to know

Twill hunts for pharma partner to market its depression app

Medicare proposal to cover medical devices draws a mixed reaction

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Drug repurposing or repositioning? The language matters

House passes resolution saying Israel isn't a 'racist or apartheid state'

New air purifier tech could be key to improving indoor air quality

FDA needs staff influx to meet gene therapy needs, Marks says

explore

Patients' immediate access to test results puts radiologists in a bind

FDA seeking to stop procedures at two unregulated stem cell clinics

ER docs worry over extreme heat as a 'mass casualty event'

A strong 6.5

Roche to buy Carmot Therapeutics, developer of obesity drugs

A Theranos scientist

focus

hotspot

entertainment

leisure time